Billy Jacob

Legacy media HATES Elon so much. You would never know that $TSLA is up ~5% in pre-market with these headlines. @farzyness @SawyerMerritt @elonmusk @DavidSacks

@SJD10304 @seeitmarket Steve, I just read the entire article. This "phenomenon" is fascinating! It's amazing how accurate the barometer was in calculating what happened in January 2016. It'll be interesting to see if the S&P can rally above 2810 by January 19, 2019.

if you're new to TOY, here's a piece I wrote for @seeitmarket in 2015. seeitmarket.com/maximizing-ret…

If you're tracking Whaley's TOY for 2018-19's turn of the year, write down 2,690.73. Bullish TOY triggers only with a close > 2771.45 on 1/18/2019. Interestingly, TOY's near perfect track record requires a close > 2810.30 on 1/18/2019 to remain near perfect. #spx

@SJD10304 Do we not need to retest the October low (~2640)?

+50 please. #spx

@SJD10304 Yup, I saw that tweet yesterday and actually wrote down that number. You've been very solid with your calls, regardless. I appreciate the effort you put forth in running the numbers. Thanks.

@Billy_Jacob I tried, and failed, yesterday. Second attempt, 2674.38. twitter.com/sjd10304/statu…

@SJD10304 Right now, it looks like you were correct about potential support at 2550.

Our interview on Real Vision Television. New from The Fat Pitch fat-pitch.blogspot.com/2018/06/interv…

$RYTM Also, in the same S-1 (services.corporate-ir.net/SEC.Enhanced/S…), Rhythm provides clarity on the LepR phase 3 design, specifically with regard to the eight-week placebo-controlled withdrawal period.

$RYTM In their most recent S-1 (services.corporate-ir.net/SEC.Enhanced/S…), Rhythm provides an update on Patients #2 and #3 from the phase 2 LepR trial.

@Becker_MichaelD @Forbes @matthewherper Can you get back on chemo, and then cycle off it in a year or so?

New blog post - "The Art of Dying" at mdbcancerjourney.com/2018/06/26/the… #cancer #HPV #awalkwithpurpose @Forbes @matthewherper

The primary endpoint for $RYTM's POMC and LEPR P3 trial is "patients achieving a 10 percent change from baseline." Both patients in the POMC P2 trial lost far more than 10% from baseline by Week 52.

$RYTM announced the completion of enrollment of their P3 trials in POMC and LEPR. Initial data for both trials had been guided for 1H 2019, but that has been pushed back slightly to Q3 2019. ir.rhythmtx.com/phoenix.zhtml?…

$AVXS: *Novartis to acquire AveXis for $218 per share in cash. *AveXis’ lead product candidate, AVXS-101, expected to enhance Novartis’s position as a gene therapy and neuroscience leader. *Transaction expected to be completed in mid-2018. investors.avexis.com/phoenix.zhtml?…

Lets dance. #spx

@michaellistman @Temple_Pharmacy I have Scottrade. They have just a 100% margin requirement for shorting UVXY. This is lower than Fidelity and Schwab. I don't know what'll happen after the merger, either.

@RNAiAnalyst Hey Dirk, it is intrathecal - investors.avexis.com/phoenix.zhtml?….

$AVXS "The trial will evaluate safety, dosing and proof of concept for efficacy. The trial will use product produced from the new GMP process at the AveXis(AVXS) facility. Conference call and webcast today at 4:30 p.m. EST."

$AVXS "The FDA notified AveXis(AVXS) it may initiate the Phase 1 trial in SMA Type 2 based on a review of data provided by the company; trial to commence immediately."

Baker Bros increase stake in $AVXS from 625,000 shares to 775,000 shares (+24%).

Baker Bros 13F: New - sec.gov/Archives/edgar… Previous: sec.gov/Archives/edgar… Synopsis: whalewisdom.com/filer/baker-br…